Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06250283 · ClinicalTrials.gov registry record · NA
Resveratrol for the Prevention of Bone Loss in Postmenopausal Women
A NA study of Low Bone Mass, sponsored by University of Delaware.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT06250283: Completed NA study of Low Bone Mass, sponsored by University of Delaware.
NCT06250283 is a NA study of Low Bone Mass that has completed, run by University of Delaware. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06250283, a NA study of Low Bone Mass, has completed, sponsored by University of Delaware.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.
Primary Outcome
25-hydroxy vitamin D3
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Resveratrol
Study Locations (1)
Delaware
- University of Delaware - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2026-01-30 |
| Phase | NA |
What the finished NCT06250283 record still lists
NCT06250283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Low Bone Mass appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06250283 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT06250283 about?
NCT06250283 is a clinical study titled "Resveratrol for the Prevention of Bone Loss in Postmenopausal Women". The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women.
What is the current status of trial NCT06250283?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2024-02-02. Estimated completion is 2026-01-30.
What conditions does trial NCT06250283 study?
This clinical trial studies the following conditions: Low Bone Mass.
What interventions are being tested in trial NCT06250283?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Resveratrol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06250283?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06250283 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06250283's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI